Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

Up to 10 Million Americans Could Lose Medicaid by 2028 Under New Work Requirements

by Team Lumida
April 1, 2026
in Health and Longevity
Reading Time: 3 mins read
A A
0
Auto Draft
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • Between 5 million and 10 million people could lose Medicaid coverage in 2028 due to work requirements and six-month eligibility redeterminations mandated under the One Big Beautiful Bill signed by President Trump in July
  • 2 to 3.1 million enrollees could lose coverage from the shift to semi-annual eligibility checks alone; an additional 3 to 7 million could be cut due to the new 80-hour monthly work requirement
  • 19% to 37% of those who already work and legally qualify could still be disenrolled due to paperwork and documentation challenges — not because they are ineligible
  • Even in the best-case high-mitigation scenario, Medicaid expansion enrollment drops from 18.4 million to 13.5 million — a loss of nearly 5 million covered lives

What Happened?

A new analysis by the Urban Institute and Robert Wood Johnson Foundation projects that between 5 million and 10 million people could lose Medicaid coverage in 2028 due to sweeping policy changes in the One Big Beautiful Bill, signed into law by President Trump last July. The law requires many adults who enrolled through the ACA Medicaid expansion to document 80 hours per month of work, education, or volunteer activity to maintain coverage. It also mandates eligibility redeterminations every six months instead of annually. Researchers modeled three scenarios — low, medium, and high state-level mitigation — based on how aggressively states work to protect enrollees through automatic data-matching, broader exemption definitions, and accessible documentation processes. Even under the most protective scenario, expansion enrollment falls from 18.4 million to 13.5 million — a decline of nearly 5 million people. Under the low-mitigation scenario, that figure surpasses 8 million.

Why It Matters?

This represents the largest structural change to Medicaid in decades, affecting a program that covers 76 million Americans. The financial exposure for the healthcare sector is significant: hospitals, managed care organizations, and state Medicaid budgets are all heavily dependent on continuous enrollment. The analysis reveals a particularly troubling dynamic — people who already work and qualify for the program could still lose coverage due to documentation burdens. Between 30% and 73% of self-employed enrollees subject to the work mandate could be disenrolled because automatic income verification for the self-employed is technically difficult. Caregivers of family members with disabilities face disenrollment rates of 19% to 52%, even though they are supposed to be exempt. For healthcare investors and operators, this translates directly into higher uncompensated care costs, increased bad debt, and potential pressure on Medicaid managed care plan margins.

What’s Next?

Implementation affects enrollees starting in 2028, giving states roughly two years to build the infrastructure needed to minimize unnecessary coverage losses. States that invest in automatic data-matching and broad exemption definitions will blunt the impact significantly — but political and resource constraints will vary widely. Managed care organizations with large Medicaid books of business should be closely monitoring state-level implementation plans; the difference between high and low mitigation scenarios represents millions of covered lives and billions in premium revenue. Hospital systems should be stress-testing their uncompensated care assumptions now. Congressional debate over further Medicaid cuts — including proposals to cap federal matching funds — is expected to continue through the 2026 budget cycle, adding additional uncertainty to an already volatile policy environment.

Source: Healthcare Dive

Previous Post

Oracle Slashes Thousands of Jobs to Fund Its AI Bet

Recommended For You

One-Third of Americans Now Use AI for Health Advice — and Many Are Skipping the Doctor

by Team Lumida
1 day ago
One-Third of Americans Now Use AI for Health Advice — and Many Are Skipping the Doctor

A KFF poll of 1,300+ U.S. adults finds roughly 1 in 3 now use AI for health information — as often as social media — with 40%+ uploading...

Read more

The Weight Loss Drug Race: What’s Available Now and What’s Coming Next

by Team Lumida
5 days ago
The Weight Loss Drug Race: What’s Available Now and What’s Coming Next

The obesity drug market is set for a major expansion, with Eli Lilly's once-daily pill targeting April FDA approval, Novo Nordisk launching a high-dose shot, and six additional...

Read more

GLP-1s Aren’t a Shortcut. They’re a Powerful Tool That Still Needs a Real Health Strategy

by Team Lumida
1 week ago
GLP-1s Aren’t a Shortcut. They’re a Powerful Tool That Still Needs a Real Health Strategy

Key Takeaways Powered by lumidawealth.com GLP-1 drugs can be highly effective for weight management, but they work best when combined with diet, physical activity, and clinical follow-up. The bigger...

Read more

Sleep Regularity Is the Underrated Health Lever Most People Miss

by Team Lumida
1 week ago
woman sleeping on bed under blankets

Key Takeaways Powered by lumidawealth.com A consistent sleep and wake time may be one of the simplest high-impact health habits. Healthy sleep is not just about hours. Regular timing...

Read more

Generic Ozempic Wave Could Redraw the Global GLP-1 Market

by Team Lumida
2 weeks ago
Generic Ozempic Wave Could Redraw the Global GLP-1 Market

Key Takeaways Powered by lumidawealth.com India is set to become the first major market to see a large-scale rollout of generic semaglutide, with at least a dozen major drugmakers...

Read more

Yoga Is the Longevity Habit Most People Underestimate

by Team Lumida
2 weeks ago
woman in black tank top and black pants bending her body on floor

Key takeaways Powered by lumidawealth.com Improves flexibility, balance, and joint health, reducing injury risk with age. Lowers stress and cortisol, supporting heart and metabolic health. Enhances nervous system regulation,...

Read more

Grip Strength Is a Longevity Biomarker

by Team Lumida
2 weeks ago
a person lifting a barbell in a gym

Key takeaways Powered by lumidawealth.com Lower grip strength is linked to higher mortality risk. It correlates with cardiovascular health, muscle mass, and frailty. Declining grip strength often signals system-wide...

Read more

Most “Longevity Drugs” Don’t Work the Way You Think

by Team Lumida
2 weeks ago
diagram

Key takeaways Powered by lumidawealth.com Most longevity drugs improve markers, not actual lifespan. Human evidence is weak for many popular compounds. Drug benefits are context-dependent — not universal. Lifestyle...

Read more

Walking After Meals Is a Simple Hack for Blood Sugar Control

by Team Lumida
2 weeks ago
woman walking on pathway during daytime

Key takeaways Powered by lumidawealth.com Just 10–15 minutes of walking after meals can lower post-meal blood sugar spikes. Light activity helps muscles absorb glucose without needing as much insulin....

Read more

Ozempic’s Patent Expiry Could Make India the Biggest Test Case for Cheap Weight-Loss Drugs

by Team Lumida
2 weeks ago
Ozempic’s Patent Expiry Could Make India the Biggest Test Case for Cheap Weight-Loss Drugs

Key takeaways Powered by lumidawealth.com India is about to become a major generic GLP-1 market, with multiple drugmakers preparing cheaper semaglutide launches after patent expiry. Prices could fall by...

Read more

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

China Stimulus: Enough to Sway Markets?

Big Tech Faces Tariff-Driven Digital Ad Slowdown as Economic Uncertainty Grows

April 25, 2025
SEC Drops Justin Sun Case, Signaling Faster Crypto Deregulation Under Trump

SEC Drops Justin Sun Case, Signaling Faster Crypto Deregulation Under Trump

March 6, 2026
white red and blue basketball hoop

Hedge Funds Bet Big on South Korea’s AI Chipmakers

July 11, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018